儿科医生常规治疗咳嗽的方案

B. Blokhin, G.I. Gordienko, A. Suyundukova, I. Lobushkova, V. Steshin
{"title":"儿科医生常规治疗咳嗽的方案","authors":"B. Blokhin, G.I. Gordienko, A. Suyundukova, I. Lobushkova, V. Steshin","doi":"10.24110/0031-403x-2024-103-3-122-132","DOIUrl":null,"url":null,"abstract":"Acute respiratory infections (ARI) are the main reason for morbidity in childhood. In ca. 90% of cases, they are accompanied by cough. The purpose of this research was to study the effectiveness and safety of the STODAL® drug in the treatment of cough in children. Materials and methods used: a multicenter prospective observational non-randomized clinical study was conducted involving 1000 outpatients with ARI aged 2 to 7 y/o and whose cough duration did not exceed 3 days from the onset of the disease. All of them were prescribed and treated with the complex homeopathic anticough drug on the day of their visit to pediatric practitioner in the outpatient hospital facilities. The patients were divided into two age groups as follows: G1 (n=500) of children aged 2 to 4 y/o and G2 (n=500) of children aged 4 years and 1 day old to 7 y/o. Results: on the 7th day of the therapy, a statistically significant decrease in the severity of daytime cough was noted: in G1 the severity of cough decreased by 1.51 points (from 2.16 to 0.65 points, p<0.001) and by 1.56 points (from 2.24 to 0.68 points, p<0.001) in G2. There was no difference in the reduction in daytime cough severity between the groups (p=0.158). The severity of night cough in G1 decreased by 1.16 points (from 1.64 to 0.48 points, p<0.001) and by 1.25 points (from 1.71 to 0.46 points, p<0.001) in G2. There were no differences in the dynamics of the severity of night cough between the groups as well (p=0.135). The proportion of patients whose cough resolved completely or became clinically insignificant on the 7th day of treatment was 98%, these patients were therefore considered recovered. Cough treatment was rated positively by 95.1% of parents/caretakers. Adverse events (AEs) were reported in 5 patients (0.5% of all cases) and there were no serious AEs among them. Conclusion: the effectiveness and safety of the STODAL® drug in the treatment of cough in ARI in children aged 2 to 7 y/o allows recommending a homeopathic drug with complex anti-inflammatory, antitussive and antimicrobial action for its inclusion in the treatment regimens starting from the first days of the disease.","PeriodicalId":503254,"journal":{"name":"Pediatria. Journal named after G.N. Speransky","volume":"14 21","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"TREATMENT OPTIONS FOR COUGH IN PEDIATRIC PRACTITIONER’S ROUTINE\",\"authors\":\"B. Blokhin, G.I. Gordienko, A. Suyundukova, I. Lobushkova, V. Steshin\",\"doi\":\"10.24110/0031-403x-2024-103-3-122-132\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acute respiratory infections (ARI) are the main reason for morbidity in childhood. In ca. 90% of cases, they are accompanied by cough. The purpose of this research was to study the effectiveness and safety of the STODAL® drug in the treatment of cough in children. Materials and methods used: a multicenter prospective observational non-randomized clinical study was conducted involving 1000 outpatients with ARI aged 2 to 7 y/o and whose cough duration did not exceed 3 days from the onset of the disease. All of them were prescribed and treated with the complex homeopathic anticough drug on the day of their visit to pediatric practitioner in the outpatient hospital facilities. The patients were divided into two age groups as follows: G1 (n=500) of children aged 2 to 4 y/o and G2 (n=500) of children aged 4 years and 1 day old to 7 y/o. Results: on the 7th day of the therapy, a statistically significant decrease in the severity of daytime cough was noted: in G1 the severity of cough decreased by 1.51 points (from 2.16 to 0.65 points, p<0.001) and by 1.56 points (from 2.24 to 0.68 points, p<0.001) in G2. There was no difference in the reduction in daytime cough severity between the groups (p=0.158). The severity of night cough in G1 decreased by 1.16 points (from 1.64 to 0.48 points, p<0.001) and by 1.25 points (from 1.71 to 0.46 points, p<0.001) in G2. There were no differences in the dynamics of the severity of night cough between the groups as well (p=0.135). The proportion of patients whose cough resolved completely or became clinically insignificant on the 7th day of treatment was 98%, these patients were therefore considered recovered. Cough treatment was rated positively by 95.1% of parents/caretakers. Adverse events (AEs) were reported in 5 patients (0.5% of all cases) and there were no serious AEs among them. Conclusion: the effectiveness and safety of the STODAL® drug in the treatment of cough in ARI in children aged 2 to 7 y/o allows recommending a homeopathic drug with complex anti-inflammatory, antitussive and antimicrobial action for its inclusion in the treatment regimens starting from the first days of the disease.\",\"PeriodicalId\":503254,\"journal\":{\"name\":\"Pediatria. Journal named after G.N. Speransky\",\"volume\":\"14 21\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatria. Journal named after G.N. Speransky\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24110/0031-403x-2024-103-3-122-132\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatria. Journal named after G.N. Speransky","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24110/0031-403x-2024-103-3-122-132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

急性呼吸道感染(ARI)是儿童发病的主要原因。约 90% 的病例伴有咳嗽。本研究的目的是研究 STODAL® 药物治疗儿童咳嗽的有效性和安全性。采用的材料和方法:开展了一项多中心前瞻性观察非随机临床研究,涉及 1000 名 2 至 7 岁的急性呼吸道感染门诊患者,这些患者的咳嗽持续时间自发病起不超过 3 天。所有患者均在医院门诊儿科医生处就诊当天接受了复方顺势疗法止咳药的处方和治疗。患者被分为以下两个年龄组:G1组(人数=500)为2至4岁的儿童,G2组(人数=500)为4岁零1天至7岁的儿童。结果:在治疗的第 7 天,日间咳嗽的严重程度出现了统计学意义上的显著下降:G1 组的咳嗽严重程度下降了 1.51 点(从 2.16 点下降到 0.65 点,p<0.001),G2 组的咳嗽严重程度下降了 1.56 点(从 2.24 点下降到 0.68 点,p<0.001)。两组在减轻白天咳嗽严重程度方面没有差异(P=0.158)。G1 组的夜间咳嗽严重程度降低了 1.16 点(从 1.64 点降至 0.48 点,P<0.001),G2 组降低了 1.25 点(从 1.71 点降至 0.46 点,P<0.001)。各组间夜间咳嗽严重程度的动态变化也没有差异(P=0.135)。在治疗的第 7 天,咳嗽完全消失或临床症状不明显的患者比例为 98%,因此这些患者被视为痊愈。95.1%的家长/看护人对咳嗽治疗给予了积极评价。有 5 名患者(占所有病例的 0.5%)报告了不良反应,其中没有严重不良反应。结论:由于 STODAL® 药物在治疗 2 至 7 岁儿童急性呼吸道感染咳嗽方面的有效性和安全性,因此建议将这种具有复杂消炎、止咳和抗菌作用的顺势疗法药物纳入从发病最初几天开始的治疗方案中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
TREATMENT OPTIONS FOR COUGH IN PEDIATRIC PRACTITIONER’S ROUTINE
Acute respiratory infections (ARI) are the main reason for morbidity in childhood. In ca. 90% of cases, they are accompanied by cough. The purpose of this research was to study the effectiveness and safety of the STODAL® drug in the treatment of cough in children. Materials and methods used: a multicenter prospective observational non-randomized clinical study was conducted involving 1000 outpatients with ARI aged 2 to 7 y/o and whose cough duration did not exceed 3 days from the onset of the disease. All of them were prescribed and treated with the complex homeopathic anticough drug on the day of their visit to pediatric practitioner in the outpatient hospital facilities. The patients were divided into two age groups as follows: G1 (n=500) of children aged 2 to 4 y/o and G2 (n=500) of children aged 4 years and 1 day old to 7 y/o. Results: on the 7th day of the therapy, a statistically significant decrease in the severity of daytime cough was noted: in G1 the severity of cough decreased by 1.51 points (from 2.16 to 0.65 points, p<0.001) and by 1.56 points (from 2.24 to 0.68 points, p<0.001) in G2. There was no difference in the reduction in daytime cough severity between the groups (p=0.158). The severity of night cough in G1 decreased by 1.16 points (from 1.64 to 0.48 points, p<0.001) and by 1.25 points (from 1.71 to 0.46 points, p<0.001) in G2. There were no differences in the dynamics of the severity of night cough between the groups as well (p=0.135). The proportion of patients whose cough resolved completely or became clinically insignificant on the 7th day of treatment was 98%, these patients were therefore considered recovered. Cough treatment was rated positively by 95.1% of parents/caretakers. Adverse events (AEs) were reported in 5 patients (0.5% of all cases) and there were no serious AEs among them. Conclusion: the effectiveness and safety of the STODAL® drug in the treatment of cough in ARI in children aged 2 to 7 y/o allows recommending a homeopathic drug with complex anti-inflammatory, antitussive and antimicrobial action for its inclusion in the treatment regimens starting from the first days of the disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信